SCHEMBL25613698

SCHEMBL25613698

Cc1ccc(/C=N/Nc2nc(-c3ccccc3C)cs2)c(C)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.62
▸ KMT2A Q03164 4/20 0.62
▸ MAPT P10636 3/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.62
▸ LMNA P02545 1/20 0.62
▸ GAA P10253 2/20 0.59
▸ TDP1 Q9NUW8 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ GUSB P08236 2/20 0.52
▸ DHODH Q02127 4/20 0.48
▸ EGFR P00533 3/20 0.48
▸ MAOA P21397 2/20 0.48
▸ MAOB P27338 2/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613950 0.90 DHODH (0.61) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL25613755 0.89 DHODH (0.56) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL25614112 0.89 EGFR (0.50) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL25613688 0.87 EGFR (0.52) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL25614522 0.85 DHODH (0.58) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL25614001 0.82 DHODH (0.48) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL25614555 0.81 DHODH (0.48) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL25613990 0.80 DHODH (0.69) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL25613862 0.80 GUSB (0.67) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL25613768 0.77 GAA (0.68) MEN1KMT2AMAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190713-A1 ANTI-RNA VIRUS DRUG AND APPLICATION THEREOF EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190713-A1 ANTI-RNA VIRUS DRUG AND APPLICATION THEREOF SARS1, EIF2AK2, NSUN3 MEN1 4853/4885KMT2A 4184/4885MAPT 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback